HSV-2

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Retrieved on: 
Wednesday, December 21, 2022
Ageing, Invention, RNA transfection, University of Pennsylvania, Research, Distress, HIV, Glycoprotein, Global health, Risk, BNTX, Infection, Meningitis, Herpes simplex virus, World Health Organization, HSV epigenetics, Safety, Penn, University, BioNTech, IND, Immunity, HSV, History, HSV-2, Pharmaceutical industry, Vaccine

The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163.

Key Points: 
  • The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163.
  • Editor’s Note: The University of Pennsylvania has licensed some intellectual property related to the BNT163 vaccine candidate to BioNTech.
  • The University of Pennsylvania receives sponsored research funding from BioNTech related to preclinical development of the BNT163 vaccine candidate.
  • As inventors of certain intellectual property related to the BNT163 vaccine candidate, some of the scientists involved in the preclinical development of the candidate along with Penn, may receive additional financial benefits under the BioNTech license in the future.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

Retrieved on: 
Wednesday, August 10, 2022
National Institute of Allergy and Infectious Diseases, U.S. Securities and Exchange Commission, HIV/AIDS, Association, American Association, Medical laboratory, RNA transfection, GLOBE, University of Washington Department of Global Health, Diagnosis, National Center for Advancing Translational Sciences, HIV Vaccine Trials Network, HVTN, Cancer, Leadership, Fred Hutchinson Cancer Research Center, National Institute, Infection, Board, Society, Research, NIAID, Security (finance), HSV, Vaccine, COVID-19, HSV-2, Biotechnology, Alumnus, Virology, Degenerative disease, University, Board of directors, HIV, American Association of Clinical Endocrinologists, Immune system, Pharmaceutical industry, Science, Medicine, Director, Gritstone

EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced the appointment of Lawrence Larry Corey, M.D., to its Board of Directors.

Key Points: 
  • EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced the appointment of Lawrence Larry Corey, M.D., to its Board of Directors.
  • Effective August 12, 2022, Dr. Corey replaces Richard Heyman, Ph.D. who stepped down as a Board Member after more than six years of service.
  • I would also like to sincerely thank Rich Heyman for his years of service on Gritstones Board of Directors, where he helped us develop and apply our novel platform technologies.
  • We are thrilled to have Larry join us to help guide continued advancement of Gritstones important clinical programs and unique scientific capabilities, said Dr. Elaine V. Jones, Chair of Gritstone bios Board of Directors.

Global Genital Herpes Treatment Market Outlook Report 2022-2027 Featuring Key Vendors - GlaxoSmithKline, Glenmark Pharmaceuticals, Viatris, Novartis, Teva Pharmaceuticals, & Bausch Health Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Infectious Diseases, Pharmaceutical, Health, People, FDA, LGBT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Woman, Ageing, Valaciclovir, Pharmacy, Retail, Risk, MSM, Famciclovir, Recurrence, Sex organ, Food, Simplex, Population, NE, Geography, GSK, Incidence, IND, Man, HSV, Patient, HSV-2, Company, Genital herpes, Vaccine, STD, OTC, Infection, Awareness, Immunodeficiency, Sanofi, Herpes labialis, WHO, Technology, Herpes simplex virus, HIV, Factor X, Sex, STI, Vertically transmitted infection, Investigational New Drug, Pharmaceutical industry, Birth control, Aciclovir, Aciclovir, Pritelivir, Moderna

The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.
  • HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes.
  • North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%.

Rational Vaccines Herpes Simplex Type 2 (HSV-2) Therapeutic Vaccine Candidate Demonstrates Efficacy in a Therapeutic Animal Study

Retrieved on: 
Friday, July 8, 2022
Diagnosis, Mouse, Fever, Blister, Patient, School, Biotechnology, Nerve agent, Fissure, Severe cognitive impairment, UC Davis School of Veterinary Medicine, Disease, Louisiana State University, Chills, Erythema, Infection, Company, National, LSU, Simplex, Ulcer, Veterinary medicine, Virology, Guinea, NIH, World, WHO, Western world, Genital herpes, World Health Organization, Myalgia, Virus, Human, Animal, Neonatal infection, Vaccine, Foundation for the National Institutes of Health, HSV-2, HSV, Pharmaceutical industry

WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2). Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo. In addition, RVX201 appears to generate a robust cellular immune response equivalent to that elicited by wild-type HSV-2 on Day 7 post-infection. Results showed that in comparison to no vaccine, animals that received RVX201 had the number of symptomatic days reduced by 45 percent while those that received gD2-alum/MPL vaccine only had a 24 percent reduction in symptomatic days.

Key Points: 
  • and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2).
  • Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo.
  • The herpes simplex virus (HSV), commonly referred to as herpes, is categorized into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).
  • Rational Vaccines is revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases with its rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates.

Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate

Retrieved on: 
Tuesday, June 14, 2022
Vaccine, Research, Depression, Ulcer, CEO, Immediate, WHO, RNA transfection, Risk, Technology, Encephalitis, EU, Herpes labialis, Simplex, Quality of life, Food industry, HIV, HSV-2, Documentation, Protein, Pharmaceutical industry, Pfizer

STOCKHOLM, June 14, 2022 /PRNewswire/ --Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec").

Key Points: 
  • STOCKHOLM, June 14, 2022 /PRNewswire/ --Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec").
  • Redbiotec has a right to royalties on Eurocine Vaccines net sales of an approved HSV-2 vaccine, should such sales arise.
  • "I am very pleased that we have added this promising candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine made to this point by Redbiotec," says CEO Hans Arwidsson, Eurocine Vaccines.
  • Evaluate the potential of a prophylactic HSV-2 vaccine to follow the development of this therapeutic vaccine, and the potential synergies of these two.

Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate

Retrieved on: 
Tuesday, June 14, 2022
Vaccine, Research, Depression, Ulcer, CEO, Immediate, WHO, RNA transfection, Risk, Technology, Encephalitis, EU, Herpes labialis, Simplex, Quality of life, Food industry, HIV, HSV-2, Documentation, Protein, Pharmaceutical industry, Pfizer

STOCKHOLM, June 14, 2022 /PRNewswire/ --Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec").

Key Points: 
  • STOCKHOLM, June 14, 2022 /PRNewswire/ --Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec").
  • Redbiotec has a right to royalties on Eurocine Vaccines net sales of an approved HSV-2 vaccine, should such sales arise.
  • "I am very pleased that we have added this promising candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine made to this point by Redbiotec," says CEO Hans Arwidsson, Eurocine Vaccines.
  • Evaluate the potential of a prophylactic HSV-2 vaccine to follow the development of this therapeutic vaccine, and the potential synergies of these two.

BlueWillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal COVID-19 Booster Candidate in Pre-clinical Studies

Retrieved on: 
Wednesday, March 2, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Biopharmaceutical, COVID, Urinary tract infection, HSV-2, Vaccine, Research, EV71, MVC, Vertically transmitted infection, National, Doctor of Philosophy, Safety, Immunity, RSV, Vaccination, Solution, COVID-19, GMP, Human, Patent, EUA, Trial of the century, MVC-COV1901, Food, BioRxiv, Clinical trial, Enterovirus, HSV, Achievement, Intention, MD, COVID19, Infection, Animal, MediGene, Anthrax, Medigen Vaccine Biologics (MVC) Corporation, BlueWillow Biologics, MEDIGEN VACCINE BIOLOGICS (MVC) CORPORATION, BLUEWILLOW BIOLOGICS

The study examined the responses in hamsters receiving various regimens of intramuscular-only, intramuscular primary and intranasal booster vaccine, and negative control group receiving no vaccination.

Key Points: 
  • The study examined the responses in hamsters receiving various regimens of intramuscular-only, intramuscular primary and intranasal booster vaccine, and negative control group receiving no vaccination.
  • We are excited to demonstrate that our intranasal vaccine candidate not only provides mucosal protection but also boosts the systemic immunity elicited from intramuscular vaccination against COVID-19.
  • Charles Chen, Chief Executive Officer of Medigen, commented, "We are pleased that the jointly developed intranasal vaccine has shown strong results in this preclinical study.
  • MVCs pipeline includes COVID-19 vaccine (MVC-COV1901), enterovirus EV71 vaccine, dengue vaccine, and influenza quadrivalent vaccine, which have all entered late clinical stage.

Rational Vaccines' RVX1001 Vaccine Candidate Protects Against HSV Ocular Infection in vivo

Retrieved on: 
Tuesday, December 28, 2021
People, Antibody, Fissure, Company, World, Louisiana State University, Blister, Immune system, School, Fever, Department, VC2, WHO, Infection, HK, Herpes simplex keratitis, LSU, Vaccination, Myalgia, Vaccine, Virology, UC Davis School of Veterinary Medicine, Patient, Severe cognitive impairment, McQuillan, LSU School of Music, HSV-1, Alzheimer's disease, HSV-2, HSV, Mouse, Research, Prevalence, Virus, Veterinary medicine, Diagnosis, Cornea, Frontiers, Keratitis, Neutrophil, Chills, Genital herpes, Multimedia, Erythema, Dementia, Disease, Social stigma, Biotechnology, MRCVS, World Health Organization, BVM, Doctor of Philosophy, Simplex, Ulcer, Immunology

Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.

Key Points: 
  • Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.
  • Results showed that RVX1001 administered prophylactically protected mice against lethal ocular HSV-1 challenge and the development of herpetic keratitis.
  • Herpetic keratitis induced by herpes simplex virus type 1 (HSV-1) ocular infection is a leading infectious cause of blindness.
  • Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With T Cell Intracorneal Infiltration.